Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

abemaciclib

- PMLiVE

Victoza cuts cardiovascular risk in landmark study

Novo Nordisk’s diabetes therapy outcomes ‘beyond expectations’

- PMLiVE

Biosimilar trastuzumab comparable to brand, ASCO hears

Roche’s Herceptin matched in safety and efficacy by Mylan and Biocon’s breast cancer drug

Eli Lilly HQ

Lilly planning 20 new launches by 2023

Will focus on diabetes, immunology, oncology, neurodegeneration and pain

Novartis building

Novartis says Cosentyx is ‘outpacing competitors’

Claims new psoriasis drug has almost a third of the market share in Germany alone

National Institute for Health and Care Excellence NICE logo

NICE backs freer use of SGLT2 inhibitors for diabetes

Recommendation positions Invokana, Forxiga and Jardiance as first-line treatments

- PMLiVE

Stronger together

A patient-focused strategy is high on the agenda, with a top-down approach favoured by industry leaders

Roche's Perjeta pertuzumab

NICE rejects Roche’s breast cancer drug Perjeta

Says the treatment's long-term benefits are unclear

Novartis day

Trial sets up showdown between Ibrance and Novartis’ ribociclib

Positive interim data could put the Swiss firm's breast cancer therapy in-line for early approval

regeneron headquarters

Regeneron says anti-NGF fasinumab works in pain

Clinical trial shows promise for opioid alternative

Eli Lilly HQ

Lilly’s psoriasis drug Taltz cleared in Europe

Clinicians suggest the IL-17 inhibitor has “best-in-class data”

- PMLiVE

Merck drops once-weekly diabetes drug in US and EU

Says decision is due to “business reasons” not safety or efficacy issues

AstraZeneca AZ

AZ gets $100m from Lilly as Alzheimer’s drug progresses

BACE inhibitor candidate displays ‘encouraging’ positive safety data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links